

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 2

CLAIM SUMMARY DOCUMENT

Claims 1-34. (Canceled)

Claim ~~35~~². (Currently Amended) A method for ~~inhibiting the action of TNF- α for treating nerve disorders of treating a nerve disorder mediated by nucleus pulposus in a mammal in need of such treatment, wherein said nerve disorder mediated by nucleus pulposus is caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α , comprising the step of by administering a TNF- α inhibitor comprising the step of:~~

(A) ~~administering a TNF- α inhibitor, wherein said TNF- α inhibitor is a therapeutically effective dosage to said mammal of said TNF- α inhibitor wherein said TNF- α inhibitor is selected from the group consisting of (i) a soluble cytokine receptor that blocks TNF- α activity, (ii) a monoclonal antibody that blocks TNF- α activity, and or (iii) a tetracycline or a chemically modified tetracycline that blocks TNF- α activity, to said mammal in need of such treatment thereby inhibiting TNF- α and treating said which when administered to said mammal treats a nerve disorder.~~

Claim ~~36~~². (Previously Added) The method of claim ~~35~~¹, wherein the mammal is human.

Claim ~~37~~³. (Previously Added) The method of claim ~~35~~¹, wherein the tetracycline or chemically modified tetracycline is selected from the group consisting of: tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, dedimethylaminotetracycline and bases and salts thereof.

Claim 38. (Canceled)

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 3

Claim ⁴~~39~~. (Previously Added) The method of claim ~~38~~¹, wherein said nerve disorder is nerve root injury.

Claim ⁵~~40~~. (Previously Added) The method of claim ~~39~~⁴, wherein said nerve disorder involves pain.

Claim ¹⁴~~41~~. (Currently Amended) The method of claim ~~38~~¹, wherein said nerve disorder is caused by a herniated discs disc.

Claim ²⁴~~42~~. (Currently Amended) The method of claim ~~38~~¹, wherein said nerve disorder is presents as sciatica.

Claim ³³~~43~~. (Previously Added) The method of claim ~~38~~¹, wherein said nerve disorder involves pain.

Claim 44. (Canceled)

Claim 45. (Canceled)

Claim ³⁴~~46~~. (Previously Added) The method of claim ~~35~~¹, wherein said TNF- α inhibitor is administered systemically or locally.

Claim ³⁵~~47~~. (Previously Added) The method of claim ~~35~~¹, wherein said TNF- α inhibitor is administered parenterally.

Claim ³⁶~~48~~. (Previously Added) The method of claim ~~35~~¹, wherein said TNF- α inhibitor is administered intramuscularly (i.m.), intravenously (i.v.), subcutaneously (s.c.), orally or rectally.

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 4

Claim ~~49~~³⁷ (Previously Added) The method of claim ~~48~~³⁶, wherein said TNF- α inhibitor is administered i.v. by injection or infusion.

Claim ~~50~~³⁸ (Currently Amended) The method of claim ~~48~~³⁶, wherein said TNF- α inhibitor is administered ~~is administered~~ orally at a dosage of about 20 mg to about 1,500 mg.

Claim ~~51~~³⁹ (Previously Added) The method of claim ~~48~~³⁶, wherein said TNF- α inhibitor is a tetracycline and is administered at a dosage of about 100 mg.

Claims 52-57. (Canceled)

Claim ~~58~~¹⁵ (Currently Amended) The method of claim ~~39~~¹⁴, wherein said nerve disorder involves pain.

Claim ~~59~~⁶ (New) The method of claim ~~39~~⁴, wherein the mammal is human.

Claim ~~60~~¹⁶ (New) The method of claim ~~41~~¹⁴, wherein the mammal is human.

Claim ~~61~~²⁵ (New) The method of claim ~~42~~²⁴, wherein the mammal is human.

Claim ~~62~~⁷ (New) The method of claim ~~39~~⁴, wherein the tetracycline or chemically modified tetracycline is selected from the group consisting of: tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, dedimethylaminotetracycline and bases and salts thereof.

Claim ~~63~~¹⁷ (New) The method of claim ~~41~~¹⁴, wherein the tetracycline or chemically modified tetracycline is selected from the group consisting of: tetracycline,

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 5

doxycycline, lymecycline, oxytetracycline, minocycline, dedimethylaminotetracycline and bases and salts thereof.

Claim ~~64~~²⁶. (New) The method of claim ~~42~~²⁴, wherein the tetracycline or chemically modified tetracycline is selected from the group consisting of: tetracycline, doxycycline, lymecycline, oxytetracycline, minocycline, dedimethylaminotetracycline and bases and salts thereof.

C
Cont'd
Claim ~~65~~⁸. (New) The method of claim ~~39~~⁴, wherein said TNF-alpha inhibitor is administered systemically or locally.

Claim ~~66~~¹⁸. (New) The method of claim ~~41~~¹⁴, wherein said TNF-alpha inhibitor is administered systemically or locally.

Claim ~~67~~²⁷. (New) The method of claim ~~42~~²⁴, wherein said TNF-alpha inhibitor is administered systemically or locally.

Claim ~~68~~⁹. (New) The method of claim ~~39~~⁴, wherein said TNF-alpha inhibitor is administered parenterally.

Claim ~~69~~¹⁹. (New) The method of claim ~~41~~¹⁴, wherein said TNF-alpha inhibitor is administered parenterally.

Claim ~~70~~²⁸. (New) The method of claim ~~42~~²⁴, wherein said TNF-alpha inhibitor is administered parenterally.

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 6

Claim ¹⁰~~7~~₁. (New) The method of claim ⁴~~3~~₆, wherein said TNF-alpha inhibitor is administered intramuscularly (i.m.), intravenously (i.v.), subcutaneously (s.c.) orally or rectally.

Claim ¹¹~~7~~₂. (New) The method of claim ¹⁰~~7~~₁, wherein said TNF-alpha inhibitor is administered i.v. by injection or infusion.

Claim ¹²~~7~~₃. (New) The method of claim ¹⁰~~7~~₁, wherein said TNF-alpha inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

C
Cont'd
Claim ²⁰~~7~~₄. (New) The method of claim ¹⁴~~4~~₁, wherein said TNF-alpha inhibitor is administered intramuscularly (i.m.), intravenously (i.v.), subcutaneously (s.c.) orally or rectally.

Claim ²¹~~7~~₅. (New) The method of claim ²⁰~~7~~₄, wherein said TNF-alpha inhibitor is administered i.v. by injection or infusion.

Claim ²²~~7~~₆. (New) The method of claim ²⁰~~7~~₄, wherein said TNF-alpha inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

Claim ²⁴~~7~~₇. (New) The method of claim ²⁴~~4~~₂, wherein said TNF-alpha inhibitor is administered intramuscularly (i.m.), intravenously (i.v.), subcutaneously (s.c.) orally or rectally.

Claim ³⁰~~7~~₈. (New) The method of claim ²⁹~~7~~₇, wherein said TNF-alpha inhibitor is administered i.v. by injection or infusion.

Application No. 09/743,852
Attorney's Docket No. 003300-712
Page 7

C. Cont'd
Claim ~~79~~³¹. (New) The method of claim ~~77~~²⁹, wherein said TNF-alpha inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

Claim ~~80~~¹³. (New) The method of claim ~~79~~⁴, wherein said TNF-alpha inhibitor is tetracycline and is administered at a dosage of about 100 mg.

Claim ~~81~~²³. (New) The method of claim ~~79~~¹⁴, wherein said TNF-alpha inhibitor is tetracycline and is administered at a dosage of about 100 mg.

Claim ~~82~~³². (New) The method of claim ~~79~~²⁴, wherein said TNF-alpha inhibitor is tetracycline and is administered at a dosage of about 100 mg.
